← back to search

Magdalena E. Sobieszczyk

NewYork–Presbyterian Hospital · US
Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV/AIDS Research and Interventions, HIV Research and Treatment, COVID-19 Clinical Research Studies, and SARS-CoV-2 and COVID-19 Research.
h-index
46
citations
13,738
works
213
NIH funding
primary concept
Medicine
email

Recent publications

Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers.
2026cited by 0position: contributordoi
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial
Science Translational Medicine 2025cited by 23position: middledoi
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.
2025cited by 13position: contributordoi
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)
Annals of Internal Medicine 2025cited by 11position: middledoi
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data
JAMA Network Open 2025cited by 4position: middledoi
Increased Depression and Anxiety Among Men and Transgender Women Receiving Care at a Sexual Health Clinic in New York City During COVID-19.
2025cited by 0position: contributordoi
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV
JAMA Cardiology 2024cited by 77position: middledoi
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Pharmaceutics 2024cited by 20position: middledoi
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial
PLoS Medicine 2024cited by 13position: middledoi
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
The Journal of Infectious Diseases 2024cited by 8position: middledoi
Lessons learnt from daily oral PrEP delivery to inform national planning for PrEP ring introduction for women in low-income and middle-income countries: a qualitative inquiry of international stakeholders
BMJ Global Health 2024cited by 5position: middledoi
Leveraging international stakeholders’ experiences with oral PrEP costs to accelerate implementation of the monthly dapivirine vaginal ring: A qualitative study
Health Research Policy and Systems 2024cited by 1position: middledoi
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
npj Vaccines 2023cited by 40position: middledoi
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults
JAMA Network Open 2023cited by 23position: middledoi
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Nature Communications 2023cited by 22position: middledoi
Implementation and resource needs for long‐acting PrEP in low‐ and middle‐income countries: a scoping review
Journal of the International AIDS Society 2023cited by 12position: middledoi
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1–uninfected adult participants in the US
Vaccine 2023cited by 2position: contributordoi
Effect of Participative Web-Based Educational Modules on HIV and Sexually Transmitted Infection Prevention Competency Among Medical Students: Single-Arm Interventional Study.
2023cited by 2position: contributordoi
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial
Clinical Infectious Diseases 2022cited by 40position: middledoi
SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend antibody evasion
Research Square 2022cited by 12position: middledoi
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
New England Journal of Medicine 2021cited by 527position: middledoi
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
Research Square 2021cited by 169position: middledoi
Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention
JAMA Network Open 2021cited by 78position: middledoi
Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series
BMJ 2020cited by 799position: middledoi
Bacteremia and Blood Culture Utilization during COVID-19 Surge in New York City
Journal of Clinical Microbiology 2020cited by 182position: middledoi
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019
Clinical Infectious Diseases 2020cited by 120position: middledoi
Clinical Performance of SARS-CoV-2 Molecular Tests
Journal of Clinical Microbiology 2020cited by 106position: middledoi
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial
Journal of Virology 2019cited by 31position: middledoi
Antigenic competition in CD4 <sup>+</sup> T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial
Science Translational Medicine 2019cited by 27position: middledoi
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
The Lancet HIV 2017cited by 216position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jason Zucker · Presbyterian Hospital5 papers (2020–2025) · 4 papers (2023–2026)Kathrine Meyers · Columbia University Irving Medical Center4 papers (2022–2024) · 3 papers (2023–2024)Kibret Yohannes · University of Virginia3 papers (2023–2024)Hong‐Van Tieu · NewYork–Presbyterian Hospital3 papers (2017–2025) · 3 papers (2023–2024) · 3 papers (2023–2024)Michael T. Yin · Columbia University Irving Medical Center3 papers (2021–2026) · 3 papers (2023–2024)Delivette Castor · Columbia University3 papers (2023–2024)Sergio Torres‐Rueda · London School of Hygiene & Tropical Medicine3 papers (2023–2024)Craig J. Heck · Columbia University3 papers (2023–2024)Ian Frank · Future University Hakodate3 papers (2017–2025) · 3 papers (2023–2024)M. Juliana McElrath · Fred Hutch Cancer Center3 papers (2019–2025) · 2 papers (2023–2024)Lindsey R. Baden · Harvard University2 papers (2019–2025)Lihong Liu · First Hospital of Lanzhou University2 papers (2021–2022)Michael C. Keefer · University of Rochester2 papers (2019–2025)